Binding Interactions of Antagonists with 5‐Hydroxytryptamine_3A Receptor Models

References

• Greenshaw A. J., Silverstone P. H. The non‐antiemetic uses of serotonin 5‐HT3 receptor antagonists. Drugs 1997; 53: 20–39
   PubMed Web of Science ®Google Scholar
• Unwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995; 373: 37–43
   PubMed Web of Science ®Google Scholar
• Boess F. G., Steward L. J., Steele J. A., Liu D., Reid J., Glencorse T. A., Martin I. L. Analysis of the ligand binding site of the 5‐HT3 receptor using site directed mutagenesis: importance of glutamate 106. Neuropharmacol 1997; 36: 637–647
   PubMedGoogle Scholar
• Corringer P. J., Le Novere N., Changeux J. P. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2002; 40: 431–458
   Google Scholar
• Maricq A. V., Peterson A. S., Brake A. J., Myers R. M., Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin‐gated ion channel. Science 1991; 254: 432–437
   PubMed Web of Science ®Google Scholar
• Belelli D., Balcarek J. M., Hope A. G., Peters J. A., Lambert J. J., Blackburn T. P. Cloning and functional expression of a human 5‐hydroxytryptamine 3AS receptor subunit. Mol Pharmacol 1995; 48: 1054–1062
   PubMed Web of Science ®Google Scholar
• Lankiewicz S., Lobitz N., Wetzel C. H.R., Rupprecht R., Gisselmann G., Hatt H. Molecular cloning, functional expression, and pharmacological characterization of 5‐hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol 1998; 53: 202–212
   Web of Science ®Google Scholar
• Davies P. A., Pistis M., Hanna M. C., Peters J. A., Lambert J. J., Hales T. G., Kirkness E. F. The 5‐HT3B subunit is a major determinant of serotonin‐receptor function. Nature 1999; 397: 359–363
   PubMed Web of Science ®Google Scholar
• Yan D., Schulte M. K., Bloom K. E., White M. M. Structural features of the ligand‐binding domain of the 5‐HT3 receptor. J Biol Chem 1999; 274: 5537–5541
   Google Scholar
• Steward L. J., Boess F. G., Steele J. A., Liu D., Wong N., Martin I. L. Importance of phenylalanine 107 in agonist recognition by the 5‐hydroxytryptamine3A receptor. Mol Pharmacol 2000; 57: 1249–1255
   Google Scholar
• Spier A. D., Lummis S. C.R. The role of tryptophan residues in the 5‐hydroxytryptamine3 receptor ligand binding domain. J Biol Chem 2000; 275: 5620–5625
   PubMedGoogle Scholar
• Beene D. L., Brandt G. S., Zhong W., Zacharias N. M., Lester H. A., Dougherty D. A. Cation‐π interactions in ligand recognition by serotonergic (5‐HT3A) and nicotinic acetylcholine receptors: The anomalous binding properties of nicotine. Biochemistry 2002; 41: 10262–10269
   PubMed Web of Science ®Google Scholar
• Venkataraman P., Venkatachalan S. P., Joshi P. R., Muthalagi M., Schulte M. K. Identification of critical residues in loop E in the 5‐HT3ASR binding. BMC Biochemistry 2002; 3: 15
   Google Scholar
• Hope A., Belelli D., Mair I. D., Lambert J. J., Peters J. A. Molecular determinants of (+)‐tubocurarine binding at recombinant 5‐hydroxytryptamine3A receptor subunits. Mol Pharmacol 1999; 55: 1037–1043
   Google Scholar
• Morreale A., Iriepa I., Gálvez E. The 5‐HT3 and nACh ionotropic receptors: a perspective from the computational chemistry point of view. Curr Medicinal Chem 2002; 9: 99–125
   Google Scholar
• Menziani M. C., De Rienzo F., Cappelli A., Anzini M., De Benedetti P. G. A computational model of the 5‐HT3 receptor extracellular domain: search for ligand binding sites. Theor Chim Acc 2001; 106: 98–104
   Google Scholar
• Brejc K., Van Dijk W., Klaassen R. V., Schuurmans M., Van der Oost J., Smit A. B., Sixma T. K. Crystal structure of an ACh‐binding protein reveals the ligand‐binding domain of nicotinic receptors. Nature 2001; 411: 269–276
   PubMed Web of Science ®Google Scholar
• Le Novere N., Grutter T., Changeux J. P. Models of the extracellular domain of the nicotinic receptors and of agonist‐ and Ca2+‐binding sites. Proc Natl Acad Sci USA 2002; 99: 3210–3214.25
   PubMed Web of Science ®Google Scholar
• Sine S. M., Wang H. L., Bren N. Lysine scanning mutagenesis delineates structural model of the nicotinic receptor ligand binding domain. J Biol Chem 2002; 277: 29210–29223
   Google Scholar
• Sullivan D., Chiara D. C., Cohen J. B. Mapping the agonist binding site of the nicotinic acetylcholine receptor by cysteine scanning mutagenesis: antagonist footprint and secondary structure prediction. Mol Pharmacol 2002; 61: 463–472
   Google Scholar
• Cromer B. A., Morton C. J., Parker M. W. Anxiety over GABAA receptor structure relieved by AChBP. Trends Biochem Sci 2002; 27: 280–287
   PubMed Web of Science ®Google Scholar
• Trudell J. R. Unique assignment of inter‐subunit association in GABAA α1β3γ2 receptors determined by molecular modeling. Biochim Biophys Acta 2002; 1565: 91–96
   Google Scholar
• Laube B., Maksay G., Schemm R., Betz H. Modulation of glycine receptor activity: a novel approach for the therapeutic intervention at inhibitory synapses?. Trends Pharmacol Sci 2002; 23: 519–527
   PubMed Web of Science ®Google Scholar
• Kelley L. A., MacCallum R. M., Sternberg M. J.E. Enhanced genome annotation using structural profiles in the program 3D‐PSSM. J Mol Biol 2000; 299: 501–522
   Web of Science ®Google Scholar
• Bower M., Cohen F. E., Dunbrack R. L., Jr. Sidechain prediction from a backbone‐dependent rotamer library: a new tool for homology modeling. J Mol Biol 1997; 267: 1268–1282
   PubMed Web of Science ®Google Scholar
• Laskowski R. A., MacArthur M. W., Moss D. S., Thornton J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26: 283–291
   Web of Science ®Google Scholar
• McDonald I. K., Thornton J. M. Satisfying hydrogen bonding potential in proteins. J Mol Biol 1994; 238: 777–793
   PubMed Web of Science ®Google Scholar
• Morris G. M., Goodsell D. S., Halliday R. S., Huey R., Hart W. E., Belew R. K., Olson A. J. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998; 19: 1639–1662
   Web of Science ®Google Scholar
• Cornell W. D., Cieplak P., Bayly C. I., Gould I. R., Merz K. M., Jr., Ferguson D. M., Spellmeyer D. C., Fox T., Caldwell J. W., Kollman P. A. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 1995; 117: 5179–5197
   Web of Science ®Google Scholar
• Russell R. B., Saqi M. A., Sayle R. A., Bates P. A., Sternberg M. J.E. Recognition of analogous and homologous protein folds: analysis of sequence and structure conservation. J Mol Biol 1997; 269: 423–439
   PubMed Web of Science ®Google Scholar
• Unwin N., Miyazawa A., Li J., Fujiyoshi Y. Activation of the nicotinic acetylcholine receptor involves a switch in conformation of the α subunits. J Mol Biol 2002; 319: 1165–1176
   PubMedGoogle Scholar
• Tairi A. P., Hovius R., Pick H., Blasey H., Bernard A., Surprenant A., Lundström K., Vogel H. Ligand binding to the serotonin 5HT3 receptor studied with a novel fluorescent ligand. Biochemistry 1998; 37: 15850–15864
   PubMed Web of Science ®Google Scholar
• Yan D., Pedersen S. E., White M. M. Interaction of D‐tubocurarine analogs with the 5HT3 receptor. Neuropharmacol 1998; 37: 251–257
   Google Scholar
• Schreiter C., Hovius R., Costioli M., Pick H., Kellenberger S., Schild L., Vogel H. Characterization of the ligand‐binding site of the serotonin 5‐HT3 receptor: the role of glutamate residues 97, 224, and 235. J Biol Chem 2003; 278: 22709–22716
   Google Scholar
• Reeves D. C., Sayed M. F.R., Chau P. L., Price K. L., Lummis S. C.R. Prediction of 5‐HT3 receptor agonist‐binding residues using homology modeling. Biophysical J 2003; 84: 2338–2344
   PubMed Web of Science ®Google Scholar